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Steering Committee), Friedman, Frommer and Tern& met 
with officials from Bristol Laboratories and RikerB3M to 
review the findings that prompted the recommendation that 
encainide and flecainide be removed from CAST. 
At 8:&l AM on April 25, Food and Drug Administration 
Commissioner D . Frank Young, along with Drs. Temple 
and Lipicky, met with representatives of Riker/3M and 
Bristol Laboratories to discuss the “Dear Docto:” letter that 
would advise physicians about he CAST findings and clarify 
the companies’ changes inindications for their products as a 
result of CAST data. Dr. Bigger attended the meeting on 
behalf of the CAST investigators. The companies proposed 
to restrict promotional activities to the indication for malig- 
nant ventricular rhythmias nd to work with the Food and 
Drug Administration to relabel the drags. It was agreed that 
the CAST findings hould be communicated to physicians 
immediately and accurately. The wording of a “Dear Doc- 
tor” letter was discussed and agreed upon by the Food and 
Drug Administration and the two companies. Separate 
“Dear Doctor” letters were sent o all American physicians 
by each company starting on the afternoon ofApril 25. The 
letters included an 800 number for physicians to call for 
further information. Also, the Food and Drug Administra- 
tion outlined its intention to communicate with physicians 
through the American Medical Association’s MedNet and by 
telephone with various organizations (e.g., American Col- 
lege of Physicians, American Association of Family Prac- 
tice, American College of Cardiology, American Medical 
Association, American Association of Medical Colleges) 
later that same day. It was hoped that these organizations 
could help by communicating with their members. The 
CAST findings and the ensuing actions by the manufacturers 
of encainide and flecainide and the Food and Drug Admin- 
istration would be published in the next Food and Drug 
Administration Talk Paper. 
The press conference. There was concern at the National 
Heart, Lung, and Blood Institute that he process of discon- 
tinuing encainide and flecainide in CAST patients in more 
than 100 participating hospitals might result in leaks and 
distortions in the press. The National Heart, Lung, and 
Blood Institute, the Food and Drug Administraticta, Bristol 
Laboratories and Riker/3M agreed that a press conference 
should be held to help make physicians aware of the CAST 
findings and to avoid frightening patients with rumors and 
distortions. The plan was to give the press written back- 
ground information, present the major CAST findings and 
answer questions. 
At 1 l:oO AM on April 25 the press conference was held on 
the National Institutes ofHealth campus. Drs. Claude Len- 
fant (Director of the National Heart, Lung, and Blood 
Institute), Friedman, Bigger and David B&tow (Chairm,iu, 
CAST DSMB) described the background, conduct and find- 
ings of the CAST. Food and Drug Administration Commis- 
sioner Young and Dr. Temple stated the joint manufacturer- 
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April 17, 1989, plihlication ofthe results in a peer-reviewed 
journa! was in?ejr::ively pursued. The Executive Committee 
wrote :T draft report within I week and asked t re Coordinat- 
ing Center to provide additional data for this purpose. To 
avoid delay in publication, it was decided to base the report 
on the data summary of March 30, 1989 rather than watt for 
all :::formation on deaths to be reported and evaluated. 
Tlms, the publication :FIould present the same information 
revkwed by the CAST DSMB when they made their ecom- 
men&ion to remove ncainide and flecainide from CAST. 
Dr. Arnold Relman, Editor of the New Engkrrtd hournaf of 
Medicine, was contacted and told that the CAST investiga- 
tors intended to submit a manuscript reporting the interim 
findings. To avoid invoking the Ingelfinger rule (l-3), a letter 
from Dr. Frommer was faxed to Dr. Relman when the 
National Heart, Lung, and Blood Institute press conference 
was scheduled to release the CAST findings to inform him 
that the purpose of the press conference was 
matter of urgent importance to the public health an 
misinformation from reaching CAST patients, 
and the public. A draft of a manus 
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May 9 to 10, 1989. The manuscript was revised by the 
investigators and a manuscript was submitted to the New 
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